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Polymeric drug conjugates are a new and experimental class of drug delivery systems with pharmacokinetic promises. The
antineoplastic drug camptothecin was linked to a water-soluble polymeric backbone (MAG-CPT) and administrated as a 30 min
infusion over 3 consecutive days every 4 weeks to patients with malignant solid tumours. The objectives of our study were to
determine the maximal tolerated dose, the dose-limiting toxicities, and the plasma and urine pharmacokinetics of MAG-CPT, and
to document anti-tumour activity. The starting dose was 17 mg m
72 day
71. Sixteen patients received 39 courses at seven dose
levels. Maximal tolerated dose was at 68 mg m
72 day
71 and dose-limiting toxicities consisted of cumulative bladder toxicity.
MAG-CPT and free camptothecin were accumulated during days 1–3 and considerable amounts of MAG-CPT could still be
retrieved in plasma and urine after 4–5 weeks. The half-lives of bound and free camptothecin were equal indicating that the
kinetics of free camptothecin were release rate dependent. In summary, the pharmacokinetics of camptothecin were dramatically
changed, showing controlled prolonged exposure of camptothecin. Haematological toxicity was relativelymild, but serious bladder
toxicity was encountered which is typical for camptothecin and was found dose limiting.
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Camptothecin and analogues are an important class of potent anti-
neoplastic drugs (Kehrer et al, 2001). Camptothecin showed strong
cytotoxicity against a variety of tumour types in vitro and in vivo
(Wall and Wani, 1996; Chabot, 1997). However the water soluble
salt of camptothecin (carboxylate form) induced severe toxicity
and low tumour response rates in early phase I and II studies. Dose
limiting toxicity consisted of severe cumulative haematological
toxicity at cumulative doses of 4100 mg m
72 camptothecin.
Major other toxicities were vomiting, diarrhoea, and chemical or
haemorrhagical cystitis which were often formidable and unpre-
dictable (Moertel et al, 1972; Muggia et al, 1972). In the 1990s it
was discovered that the topoisomerase I enzyme (TopI) was the
cellular target of camptothecin and that the lactone function is
essential for anti-tumour activity (Slichenmyer et al, 1993; Rivory
and Robert, 1995; Wall and Wani, 1996). However, further clinical
development of camptothecin was hampered by its unfavourable
physical properties. Camptothecin is extremely insoluble in water
and in plasma the pH favours the conversion of the lactone into
the inactive carboxylate form (Slichenmyer et al, 1993). The half-
life of the lactone form in plasma is 12 min and within 2 h 99%
has been hydrolysed into its carboxylate form (Slichenmyer et al,
1993; Rivory and Robert, 1995; Chabot, 1997). A new approach
to overcome these drawbacks is the water soluble drug-polymer
construct MAG-CPT. MAG-CPT consists of a copolymer backbone
(methacryloylglycinamide, MAG) to which camptothecin is cova-
lently conjugated at the C-20 position via an amino acid spacer
(Figure 1). The release of free camptothecin into the blood stream
is now dependent on the rate of pH mediated (and enzyme
mediated) esterolytic cleavage of MAG-CPT (Conover et al,
1999). An important potential advantage of polymeric drugs is
the so called ‘enhanced permeability and retention’ (EPR) effect
(Seymour, 1992). Whereas systemic exposure of the cytotoxic drug
is diminished by attachment to the polymeric carrier, an accumu-
lation takes place at the tumour site due to the increased
vasopermeability of many tumours. In pre-clinical experiments
decreased toxicity of normal tissue and improved anti-tumour efﬁ-
cacy probably due to prolonged intra-tumour retention could be
demonstrated (Caiolfa et al, 2000; Conover et al, 1998). To study
the pharmacokinetics of MAG-CPT polymer bound drug as well
as free drug should be considered. Objectives of our study were
(1) to determine the maximal tolerated dose (MTD) and dose-
limiting toxicities (DLT) of MAG-CPT, (2) to determine the plas-
ma and urine pharmacokinetic proﬁle of MAG-CPT and free
camptothecin and (3) to document any anti-tumour activity.
PATIENTS AND METHODS
Eligibility criteria
Patients with histological or cytological proof of malignant solid
tumour, for whom no recognised therapy was available for their
disease, were eligible. Other eligibility criteria included age 518
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and estimated life expectancy 512 weeks (Who, 1979). Previous
chemotherapy had to be discontinued for at least 4 weeks before
entry into the study, or 6 weeks in case of mitomycin C or nitro-
sourea. Patients had to be recovered from all acute toxic effects
(excluding alopecia and grade 1 neurotoxicity) from any prior
therapy. Patients had to have acceptable bone marrow function
deﬁned as absolute neutrophil count (ANC) 52000 ml
71 and
platelet count 5100000 ml
71; adequate hepatic function deﬁned
as serum bilirubin, alanine-aminotransferase (ALAT) and aspar-
tate-aminotransferase (ASAT) within normal limits or when
patients had liver metastases ALAT and ALAT 4ﬁve times under
normal limits (National Cancer Institute Common Toxicity Criter-
ia (NCI-CTC) grade 2), and bilirubin 4NCI-CTC grade 1; and
adequate renal function deﬁned as serum creatinine 41.5 mg dl
71
or 133 mmol l
71 and calculated creatinine clearance according to
described formulas (Lott and Hayton, 1978; Traub and Johnson,
1980; NCI, 1998). Ineligibility criteria included a history of treat-
ment with other camptothecins and/or more than two prior
chemotherapies for metastatic disease, intensive ablative regimens
requiring peripheral stem cell transplantation or autologous bone
marrow transplantation, prior radiotherapy to more than 25% of
the bone marrow bearing areas, known brain or leptomeningeal
disease, severe systemic disease, haematological malignancies,
known hepatitis B or HIV positive or AIDS-related illness. The
study protocol was approved by the Medical Ethics Committee
of the hospital, and all patients gave written informed consent.
Toxicity and response evaluation
Pre-treatment evaluation included a complete medical history and
complete physical examination. Before each course, a complete
physical examination was performed. Furthermore, blood chemis-
try and haematology proﬁles were checked, and urinalysis was
done. Before, immediately after and 1 h after each MAG-CPT infu-
sion the blood pressure was measured. Complete blood cell counts
were repeated weekly until occurrence of ﬁrst grade 1 leukocytope-
nia or neutropenia and twice a week thereafter, and blood
chemistries and urinalysis were done weekly. In addition, urea,
creatinine and electrolytes were measured 24 h after the ﬁrst dose
of MAG-CPT in each cycle. Electrocardiograms and tumour
measurements (by physical examination, chest X-ray, other radi-
ological investigations or ultrasound) were performed every three
cycles. All toxicities were graded according to the NCI-CTC
(NCI, 1998). Dose-limiting toxicities were deﬁned as any of the
following events occurring during the ﬁrst treatment cycle and
attributable to MAG-CPT: (1) grade 4 neutropenia lasting 5 days
or of any duration associated with infection of severity 53, (2)
febrile neutropenia, (3) grade 3 or 4 thrombocytopenia or (4)
grade 3 or 4 non-haematological toxicity (grade 2 for neurotoxi-
city) excluding nausea/vomiting responsive to treatment, fatigue
and alopecia. The maximum tolerated dose (MTD) was deﬁned
as the dose at which two of three or two of six patients experienced
DLT. The next lower dose-level below the MTD was the recom-
mended dose for phase II studies. Responses were determined
according to the WHO criteria (Who, 1979).
Dose escalation
Dose escalation was performed according to a modiﬁed Fibonacci
series in which dose increments for succeeding levels are deﬁned as
100, 67, 50 and 40% followed by 33% for all subsequent levels.
According to Simon et al (1997) an accelerated titration design
was used by entering one patient per dose-level. Before entering
a new patient at the next dose-level, the previous patient had to
be followed for 4 weeks. Treatment cycles were repeated every 28
days provided patients had sufﬁciently recovered from any drug-
related toxicity associated with the previous course (non-haemato-
logical toxicity grade 1, alopecia excluded, and return of blood
counts to 2000 ml
71 neutrophils and 100000 ml
71 platelets).
Drug administration
MAG-CPT was supplied by Pharmacia & Upjohn (Milan, Italy) in
vials containing 0.5 g of active ingredient (50 mg of camptothecin
equivalent) and lactose, polysorbate 80 as excipients and 1 N
sodium hydroxide as pH adjusting agent. All doses are expressed
as camptothecin equivalent. The content of each vial was reconsti-
tuted with 5 or 10 ml of 0.9% sodium chloride and subsequently
diluted. MAG-CPT was administered intravenously through a
central or peripheral venous access device over 30 min by a syringe
pump. Before and after infusion the venous access was ﬂushed with
a small volume of 0.9% sodium chloride.
Pharmacokinetics
Complete pharmacokinetic studies were performed during the ﬁrst
treatment course. On day 1 blood samples (5 ml each), drawn
from an indwelling intravenous cannula placed in the arm contral-
ateral to the arm receiving MAG-CPT, were collected in cooled
heparinised tubes pre-infusion, and at 15, 30, 40, 60, and
90 min, and 2.5 and 5.5 h after the start of the infusion. On day
2, samples were collected prior to infusion and at 30 min, and
4.5 and 8.5 h after the start of the infusion. On day 3, samples were
collected prior to infusion and at 30 and 50 min, and 3.5, 6.5, 24
and 48 h after the start of the infusion. Additional samples were
collected weekly thereafter until start of next cycle. Blood samples
were immediately immersed in ice-water at the bed-side. Plasma
was obtained by refrigerated centrifugation of the samples
(5 min; 3000 g,4 8C). For the determination of free camptothecin,
0.25 ml of plasma was added to 0.75 ml 8.5% phosphoric acid and
subsequently mixed on a whirl mixer for 10 s. Plasma and plasma
phosphoric acid mixture were stored in polypropylene tubes and
immediately put in a dry ice/ethanol bath and thereafter stored
by 7708C until analysis. Urine was collected at days 1, 2 and 3
with timed collections (0–8, 8–24 h) and 0–24 h at day 4 of
the ﬁrst course. A sample of each urine portion was taken and
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Figure 1 Chemical structure of MAG-CPT.
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urine-samples were collected weekly thereafter until start of the
next cycle.
Plasma levels of MAG-CPT and free camptothecin were deter-
mined using a validated reversed-phase HPLC system with
ﬂuorescence detection by Pharmacia and Upjohn (Milan, Italy)
(Schoemaker et al, 2001). Total camptothecin levels were determined
after hydrolysis of MAG-CPT and free camptothecin was extracted
from acidiﬁed plasma before determination. Concentrations of poly-
mer-bound camptothecin were calculated by subtraction of free from
total camptothecin. The lower limit of quantiﬁcation (LLOQ) of the
methods were 100 ng ml
71 for total and 1.1 ng ml
71 for free CPT
using 50 and 250 ml plasma, respectively. Determination of levels of
total MAG-CPT in urine was performed with a similar method.
The LLOQ in urine for total camptothecin was 100 ng ml
71. The
pharmacokinetic parameters were calculated using a model-indepen-
dent method using WinNonlin package (version 2.1, Scientiﬁc
Consulting Inc., 1996). Carrier-bound CPT levels were calculated
by subtracting free CPT to total CPT. For the pharmacokinetic calcu-
lations the actual sampling times were used. Pre-dose plasma levels
were put equal to zero. After MAG-CPT administration, the maxi-
mum plasma concentration (Cmax) and the corresponding time
were taken directly from the raw data for each subject. The terminal
rate constant k was determined by log-linear regression analysis of the
terminal phase of the plasma concentration-time curve. The choice of
number of points of the terminal phase was based on visual inspec-
tion of the data. The area under the plasma concentration-time
curve between 0 and 96 h, AUC0–96, was estimated by the linear-
logarithmic trapezoidal method from data points ranging from
pre-dose until 96 h after dosing. The total AUC, AUC?, was deter-
mined by the linear trapezoidal rule up to the last detectable
concentration, beyond that time, extrapolation was performed from
the last measured data point to inﬁnity using k (Clast /k). Total body
clearance of MAG-CPT from plasma (Cl) after intravenous adminis-
tration was calculated as the total administered dose divided by
AUC?. The free to bound ratio of MAG-CPT (ratiof/b)was calculated
by dividing the total AUC of free camptothecin by the total AUC of
bound camptothecin times 100%. The terminal half-life (t½) was
calculated as 0.693/k. The percentage of the administered dose recov-
ered in urine over 4 days was calculated as the amount excreted in
urine divided by the total administered dose. Total renal clearance
(ClR) of MAG-CPT was calculated as the amount excreted in urine
unchanged divided by the AUC0–96of bound CPT. Data are repre-
sented as mean+s.d.
Statistical analysis
The Pearson correlation coefﬁcient (r) was calculated between
dose, the AUC of MAG-CPT and free camptothecin. Patient’s,
haematological, and biochemical parameters (including markers
for hepatic and renal function) were correlated to pharmacokinetic
parameters of MAG-CPT and free camptothecin using the non-
parametric Spearman rank correlation test (rs) to investigate deter-
minants in inter-patient pharmacokinetic variability. Statistical
analysis was performed with SPSS (Statistical Package for Social
Sciences, version 6.1 for Windows). The level of signiﬁcance (P)
was set at 0.05. All tests for signiﬁcance were two-tailed.
Pharmacokinetic-pharmacodynamic analysis
Relationships between pharmacokinetic parameters of bound and
free camptothecin and categorical toxicity data (nausea, vomiting,
and dysuria) were explored using the Spearman rank correlation
test. Relationships between the dose and the AUC of MAG-CPT
and free camptothecin and myelosuppression were explored using
scatter plots of the AUC vs the percentage decrease in white blood
cell (WBC) count, ANC, and platelet count of the ﬁrst cycle. The
percentage decrease in blood cells is deﬁned as: (100 6 (baseline
count–nadir count))/baseline count. The data were ﬁtted using
(log)-linear and sigmoidal maximum effect (Emax) models using
the software package WinNonlin
TM (version 3.0, Pharsight
corporation). Only data obtained in the ﬁrst cycle were used.
RESULTS
Patients and treatment
Sixteen patients received a total of 39 courses at seven dose-levels
with a median of 2 (range 1–5) courses per patient. Patient char-
acteristics are outlined in Table 1. The following dose-levels were
evaluated: 17, 34, 57, 68, 85, 100, 130 mg m
72 day
71 for 3 days.
Fifteen patients were assessable for toxicity during the ﬁrst course.
Fully evaluable pharmacokinetic data were available of 15 patients.
One patient was not evaluable for toxicity and pharmacokinetics
during the ﬁrst course because of infusion leakage on the ﬁrst
day of treatment. No MAG-CPT or free camptothecin could be
detected in his blood samples collected on this day. Four patients
did not receive a second course according to this protocol, because
of rapid progressive disease.
Haematological toxicity
Haematological toxicity was rare with MAG-CPT administered in
this schedule. Serious non dose limiting haematological toxicity
was only encountered in one patient at dose-level 5 with one
episode of grade 3 leukocytopenia combined with grade 4 neutro-
penia and in one patient at dose-level 7 with one episode of grade
3 neutropenia.
Non-haematological toxicity
Bladder toxicity, consisting of sustained frequent dysuria and micro-
scopic or macroscopic haematuria was dose limiting. In Table 2 the
incidence and duration of dysuria is given because no adequate ofﬁ-
cial grading system for this kind of toxicity is available. Dysuria and
haematuria was only noted in patients treated at dose-level 4
(68 mg m
72 day
71) and higher. Symptoms generally started during
the ﬁrst or the second course and seemed initially mild to moderate.
However some of the patients who received more than one course
gradually developed very signiﬁcant toxicity. One patient at dose-
level 6 and two patients at dose-level 7 were treated after the onset
of the symptoms with sodiumbicarbonate with minor results. Most
patients had their symptoms gradually resolved after withdrawal of
MAG-CPT. After evaluation of this apparently cumulative toxicity it
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Table 1 Patient characteristics
No. of patients 16
Male/female 9/7
Median age, years (range) 56 (40–72)
Performance status
07
19
Primary tumour site
Colorectal 12
Ovarian 2
Oesophagus 1
Stomach 1
Prior chemotherapy
Median number of previous regimes (range) 2 (1–7)
Prior radiotherapy 5
For abbreviations see Patients and methods section.
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more patients were to be treated with MAG-CPT at this schedule
at these high dose-levels. Proposed dosing scheme for further inves-
tigation is 68 mg m
72 day
71 for 3 days every 4 weeks with
coadministration of 46 1000 mg day
71 carbohydrate starting
24 h before MAG-CPT because at a dose of 85 mg m
72 day
71
for 3 days every 4 weeks was the ﬁrst dose level in which two of three
patients experienced this kind of toxicity. Other non-haematological
toxicity was generally mild (CTC 42) except for one patient who
experienced grade 3 nausea during one course. Main toxicity
included nausea (10 patients), vomiting (ﬁve patients), diarrhoea
(four patients), and fatigue (three patients).
Efﬁcacy
A number of 11 out of 16 patients were evaluable for response after
two courses. The main reason for being not evaluable at ﬁrst
formal evaluation was early disease progression. No responses were
found, however one patient with colon cancer had a stable disease
which lasted for 62 days.
Pharmacokinetics
A summary of the overall pharmacokinetics of MAG-CPT is listed
in Tables 3 and 4. Mean plasma concentration-time curves of
bound and free camptothecin of patients treated with
68 mg m
72 day
71 MAG-CPT are presented in Figure 2. Plasma
levels of free camptothecin were approximately 100-fold lower than
bound camptothecin. The mean terminal elimination half-life (t½)
of bound camptothecin was 8.3+0.8 days (mean+s.d.) and of free
camptothecin 10.2+4.8 days (mean+s.d.). There is no signiﬁcant
difference between the half-lifes of bound and free camptothecin
(P=0.3). In Figure 3 the AUC of free and bound camptothecin is
given as a function of the total dose (mg m
72) of MAG-CPT. Both
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Table 2 Bladder toxicity
Dose No. of No. of
Dysuria
Duration of
mg m
72 patients courses Grade 1 Grade 2 Grade 3 Grade 4 dysuria (days)
b
17 1 3 0/0
a 0/0 0/0 0/0 NA
34 1 1 0/0 0/0 0/0 0/0 NA
57 1 5 0/0 0/0 0/0 0/0 NA
68 3 11 1/2 1/3 0/0 0/0 0 (0–154)
85 3 5 2/3 1/1 0/0 0/0 19 (0–106)
100 3 6 2/3 0/0 0/0 0/0 46 (0–78)
c
130 4 8 2/2 3/4 0/0 0/0 112 (0–154)
c
aNo. of patients developing toxicity/No. of courses causing toxicity.
bMedian data; numbers in parentheses show range.
cDysuria was not resolved (stable condition) of one patient at the end of the follow up.
Table 3 Pharmacokinetic parameters of bound camptothecin after administration of intravenous MAG-CPT for 3 days. Data
are listed as means+s.d.
Bound camptothecin
Dose Dose No. of AUC0–96 AUC? Cmax Cl T½
mg m
72 day
71 mg day
71 patients h.mgm l
71 h.mgm l
71 mgm l
71 ml h
71 day
17 30 1 481 1147 12 78.5 3.9
34 62 1 748 2491 21 74.7 6.7
57 100 1 2317 10404 54 28.8 11.3
68 133+20 3 2438+325 8661+1321 56+10 46.8+10.1 7.9+2.0
85 148+24 3 4074+130 18606+4580 103+30 24.6+6.7 10.1+2.4
100 187+13 3 15208+3101 15208+3101
a 90+14 36.5+4.5
a 7.9+2.0
a
130 238+25 3 4712+1700 –
b 94+20 –
b –
b
Abbreviations: please refer to Patients and methods section.
an=2.
bTerminal half-life could not be calculated.
Table 4 Pharmacokinetic parameters of free camptothecin after administration of intravenous MAG-CPT for
3 days. Data are listed as means+s.d.
Free camptothecin
Dose Dose No. of AUC0–96 AUC? Cmax T½ Ratiof/b
mg m
72 day
71 mg day
71 patients h.mgm l
71 h.mgm l
71 mgm l
71 day %
17 30 1 1.1 3.7 0.017 5.8 0.32
34 62 1 2.1 9.9 0.032 10.3 0.40
57 100 1 3.8 15.7 0.052 10.0 0.15
68 133+20 3 9.7+3.6 37.3+14.6 0.17+0.95 6.9+2.2 0.45+0.25
85 148+24 3 17.4+11.7 104+57 0.31+0.24 10.1+4.2 0.54+0.16
100 187+13 3 12.0+1.9 76.1+45.5
a 0.18+0.04 17.5+4.7
a 0.54+0.41
130 238+25 3 31.4+18.4 82.1+5.6
a 0.54+0.27 13.2+6.4
a –
b
Abbreviations: please refer to Patients and methods section.
an=2.
bTerminal half-life could not be calculated.
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tothecin (r=0.61, P=0.025) increase linearly with the MAG-CPT
dose. The urine excretion data are summarised in Table 5. The
bulk of the dose excreted in the urine was recovered within the
3 days of MAG-CPT administration. At day 4 only small amounts
of camptothecin were excreted in the urine (1–4% of total dose).
At 4 weeks after administration of MAG-CPT concentrations of
total camptothecin in urine of patients treated at dose levels 2–7
could still be measured (results not shown).
Statistical analysis
Two renal function parameters, potassium and urea, were consid-
ered signiﬁcant determinants of inter-patient pharmacokinetic
variability (Table 6) after univariate analysis. Potassium levels were
signiﬁcant determinants of the ratiof/b. Urea levels were signiﬁcant
determinants of the ratiof/b and AUC? of free camptothecin/dose
MAG-CPT but not for the AUC? of bound camptothecin/dose
MAG-CPT.
Pharmacokinetic-pharmacodynamic analysis
Patients with dysuria in one or more courses had signiﬁcant higher
AUC0–96 of bound camptothecin compared to patients without
dysuria (P=0.014, Figure 4). The AUC? of free camptothecin
and the dose of MAG-CPT was signiﬁcantly correlated with the
decrease in ANC, platelets, and WBC. Furthermore, a signiﬁcant
correlation was found between the AUC? of bound camptothecin
with the decrease in ANC. The decrease in WBC and ANC was
most signiﬁcant correlated with the dose (D) of MAG-CPT and
this relation was best ﬁt to a sigmoidal Emax model (parameters:
Emax=53.3%; D50=140 mg; g=7.4, and Emax=100%; D50=123 mg;
g=5.6 for WBC and ANC, respectively) (Figure 5). The decrease
in platelets was most signiﬁcant linearly correlated with the dose
of MAG-CPT (r=0.63, P50.011), however the data did not ﬁt to
a sigmoidal Emax model (results not shown).
DISCUSSION AND CONCLUSION
Over the past few decades signiﬁcant advances have been made in
technologies aimed at enhancing the pharmacological distribution
properties of anti-cancer drugs. Synthetic drug-polymers are devel-
oped to control release and targeting of cytostatics. Recently the
ﬁrst clinical experiences were described of two copolymer
constructs, with conjugated doxorubicin (PK-1) and paclitaxel
(PNU 166945) (Vasey et al, 1999; Meerum Terwogt et al, 2001).
PK-1 showed anti-cancer activity and the polymer-drug conjuga-
tion was able to decrease doxorubicin dose-limiting toxicities
while no polymer associated toxicity was observed. The compound
is currently tested in a phase II clinical trial. The phase I study with
polymer bound paclitaxel was aborted prematurely due to accumu-
lative and probable irreversible neurotoxicity found in a 13-week
rodent study conducted at the same time. However, toxicity of
polymer bound paclitaxel in patients at the achieved dose-levels
was generally mild while activity was observed in one patient with
breast cancer. We performed a clinical phase I study with MAG-
CPT, a HPMA polymer conjugate of CPT (Figure 1). The starting
dose of 17 mg m
72 day
71 for 3 days (i.e. 51 mg m
72) every 4 weeks
was based on animal data. The dose corresponds with 1 out of 3 of
the NOEL (no observed effective level, 1.5 mg kg day
71) in the
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Table 5 Urinary excretion of total camptothecin after intravenous ad-
ministration of MAG-CPT
Dose Urinary ClR
mg m
72 day
71 n excretion % ml h
71
17 1 84 157
34 1 57 141
57 1 81 105
68 3 52+68 7 +25
85 3 58+56 3 +7
100 2 97+19 105+47
130 3 68+9 197
a
Mean 68+17 105+45
an=1. For abbreviations see Patients and methods section.
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7.5 mg kg
71 or 145 mg m
72). Studies in animals demonstrated
that MAG-CPT is better tolerated when given on a split-dose basis
compared to a single administration. Three consecutive days of
intravenous treatment has been selected as a safe and convenient
therapy modality, which has the advantage to minimise patient’s
hospitalisation. The highest administered dose of MAG-CPT to
patients in this phase I study was 130 mg m
72 day
71 for 3 days
every 4 weeks. We found, however, no activity of MAG-CPT but
the number of patients evaluable for efﬁcacy in this study was very
low and the patients participating in this study were heavily pre-
treated.
Haematological toxicity of MAG-CPT at the investigated doses
and schedule was mild. In addition, haematological toxicity was
related to the administered dose. Unfortunately, bladder problems
including dysuria and microscopic and sometimes macroscopic
haematuria proved to be dose-limiting. These toxicities were only
observed at the dose-levels of 68 mg m
72 day
71 and higher. In
pre-clinical studies with MAG-CPT in rodents and dogs no bladder
toxicity was observed (Wall and Wani, 1996; Chabot, 1997). In
previous clinical studies with the sodium salt of camptothecin dose
limiting toxicity consisted of haematological depression. But also
haemorrhagical and chemical cystitis of the bladder was observed
(Moertel et al, 1972; Muggia et al, 1972). These observed urological
toxicities might be explained by the acidic environment in the
bladder which favours the formation of the insoluble lactone form
of camptothecin. Patients at the highest dose level (130 mg m
72
MAG CPT) were treated with sodium bicarbonate after onset of
their symptoms with minor result. A potential better approach to
overcome this toxic effect is to alkalise the urine by treating the
patients concomitantly with sodium bicarbonate. A drawback of
this approach is that MAG-CPT circulates in the body for a rela-
tively long time and this will mean that patients should be
alkalinised during that time. Patients experiencing complaints of
dysuria had a signiﬁcant higher AUC0–96 of bound camptothecin
indicating that renal toxicity often encountered after one or more
courses might be predicted by pharmacokinetic parameters derived
in the ﬁrst course. Two markers of renal function (potassium and
urea) were found to be clinical indicators of variance in free camp-
tothecin, but not in bound camptothecin. This provides
preliminary evidence for altered pharmacokinetics of MAG-CPT
in patients with impaired renal function.
Pharmacokinetics showed dose proportionality of bound and
free camptothecin. A linear relationship was observed for the
AUC? of bound (r=0.83, P50.002) camptothecin with dose
(mg m
72). Also free camptothecin showed a signiﬁcant linear
correlation (r=0.61, P50.025) with dose (mg m
72) in spite of
high interpatient variation in AUC? at the higher dose levels.
No difference in terminal half-lives of bound and free camptothe-
cin or clearance of bound camptothecin was found between dose
levels. The administered dose was mainly excreted by the kidneys
and 69+18% (mean+s.d.) of the dose was recovered in the urine
within 4 days. The half-life of free camptothecin was considerably
increased (11.2+9.4, mean+s.d.) compared to conventionally
administered camptothecin (Rivory and Robert, 1995; Chabot,
1997). The half-lives of bound and free camptothecin were equal
indicating that the kinetics of free camptothecin was dependent
of the release rate from its polymer carrier. In (pre-) clinical
studies with similar drug-polymer constructs a prolonged presence
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Figure 4 Plot of the AUC0–96 of bound camptothecin against the
occurrence of dysuria during all courses of individual patients, P of differ-
ence is 0.014. Bars indicate mean values.
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Figure 5 The percentage decreases in WBC (solid line) and ANC
(dashed line) during the ﬁrst course vs the daily dose. The lines indicate
the best ﬁt of the data to the sigmoidal maximal effect pharmacodynamic
model (coefﬁcient of correlation is 0.75 and 0.84 for WBC and ANC, re-
spectively).
Table 6 Inﬂuence of patient’s renal function parameters on the pharmacokinetic parameters of
free camptothecin and bound camptothecin course (Spearman Rank Order)
Bound camptothecin Free camptothecin
AUC0–96/dose
MAG-CPT
AUC0–96/dose
MAG-CPT Ratiof/b
Parameter rsp P-value rsp P-value rsp P-value
Potassium 70.16
a 0.64 0.42
c 0.15 0.69
a 0.02
Urea 0.28
b 0.46 0.84
a 0.001 0.80
d 0.01
an=11,
bn=10,
cn=13,
dn=9. For abbreviations see Patients and methods section.
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2000). This increased half-life might be of potential beneﬁt because
camptothecin and analogues are found to be cell-cycle speciﬁc
drugs and prolonged exposure could increase anti-tumour activity
(Kingsbury et al, 1990; Houghton et al, 1995). As a result of their
relatively long half-life both bound and free camptothecin accumu-
lation takes place in plasma during the 3 days of administration
and detectable levels of drug were observed in urine and plasma
of most patients just prior the next administration. This could
be an explanation for the seemingly accumulated dose related toxi-
city observed in some patients. Hence, toxicity might also be
avoided by increased time intervals between dosing, or by admin-
istration of a single dose. The ratio of free and bound
camptothecin is not signiﬁcantly different between dose-levels,
however there is a trend that this ratio increases with increasing
dose possibly indicating a possible induction in involved esterolytic
enzymes.
In summary we conclude that the pharmacokinetics of camp-
tothecin are substantially changed by binding it to a polymeric
backbone, showing controlled prolonged exposure of camptothe-
cin. Haematological toxicity was relatively mild, but we
encountered serious sustained bladder toxicity. Further investiga-
tion with MAG-CPT is warranted, but with other dosing
schedules and/or with protective measures against bladder toxicity.
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